GleamWall
中文EN

NTRA Natera, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1604821 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.4%
TTM net income YoY46.7%
TTM EPS YoY51.1%
Revenue 3-yr CAGR43.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-9.0%
Net margin-5.7%
FCF margin1.8%
EBITDA margin-7.1%

Returns

ROE-10.6%
ROA-7.2%
ROIC (approx.)-41.9%
Asset turnover1.27x

Leverage & solvency

Liabilities / assets32.0%
Debt / equity0.00x
Current ratio2.81x
Interest coverage-70.84x

Cash quality & payout

Operating cash flow / net income-1.29x
Accruals ratio-16.5%
Payout ratio—
Capex / revenue5.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$793.98M$752.75M$696.64M$665.50M$592.18M$546.60M$501.83M$476.06M
R&D expense$242.43M$228.07M$210.70M$175.19M$173.41M$146.43M$129.08M$129.46M
SG&A expense$333.66M$327.20M$327.94M$291.30M$308.55M$310.55M$266.86M$234.92M
Operating income-$68.32M-$75.79M-$93.52M-$22.79M-$97.58M-$110.37M-$79.18M-$64.74M
Interest expense$903,000$890,000$892,000$991,000$1.04M$1.03M$1.00M$1.29M
Pretax income-$59.61M-$67.23M-$84.81M-$13.33M-$87.34M-$100.66M-$66.76M-$55.13M
Income tax$299,000-$261,000$283,000-$60.58M$207,000$275,000$173,000-$1.35M
Net income-$59.91M-$66.97M-$85.09M$47.26M-$87.54M-$100.94M-$66.94M-$53.77M
EBITDA-$53.62M-$62.69M-$79.00M-$10.41M-$88.28M-$101.47M-$69.94M-$56.95M
EPS (basic)-0.42-0.47-0.60—-0.64-0.74-0.50—
EPS (diluted)-0.42-0.47-0.60—-0.64-0.74-0.50—
Weighted avg. shares (diluted)144.07M143.28M141.50M—137.19M136.39M134.75M—
Banking
Provision for credit losses$295,000$1.35M-$222,000—-$626,000-$411,000-$195,000—
Balance sheet
Cash & equivalents$1.10B$1.09B$1.09B$1.08B$1.04B$1.00B$973.77M$945.59M
Short-term investments————$1.00M$15.97M$17.83M$22.69M
Receivables$471.35M$421.97M$417.60M$296.53M$286.38M$309.22M$318.23M$314.17M
Inventory$91.70M$80.35M$70.72M$68.44M$64.64M$54.27M$50.37M$44.74M
Current assets$1.72B$1.66B$1.65B$1.50B$1.45B$1.43B$1.42B$1.38B
PP&E, net$353.95M$317.57M$269.38M$241.18M$206.50M$189.22M$180.45M$162.05M
Goodwill$141.10M$141.10M$140.86M$141.07M————
Intangibles$353.04M$360.20M$367.36M$373.71M———$10.93M
Total assets$2.75B$2.66B$2.61B$2.40B$1.82B$1.76B$1.73B$1.66B
Current liabilities$612.90M$553.20M$558.26M$441.23M$442.02M$384.84M$365.68M$344.05M
Short-term debt$80.30M$80.29M$80.31M$80.32M$80.34M$80.34M$80.34M$80.36M
Total liabilities$878.86M$836.00M$840.38M$685.93M$569.29M$510.88M$492.69M$465.31M
Shareholders' equity$1.87B$1.82B$1.77B$1.71B$1.25B$1.25B$1.24B$1.20B
Shares outstanding144.34M143.61M142.73M139.69M137.53M136.76M135.93M132.65M
Cash flow statement
Operating cash flow$43.93M$54.79M$40.17M$73.89M$59.39M$37.57M$44.45M$52.89M
Capital expenditure$38.68M$63.43M$22.14M$36.07M$22.41M$25.90M$21.82M$18.12M
Free cash flow$5.25M-$8.64M$18.03M$37.82M$36.98M$11.68M$22.64M$34.77M
Investing cash flow-$38.92M-$63.43M-$32.14M-$71.59M-$19.91M-$23.90M-$16.82M-$11.12M
Financing cash flow$684,000$12.21M$3.76M$32.41M$1.94M$12.58M$544,000$10.97M
Depreciation & amortization$14.70M$13.10M$14.52M$12.38M$9.30M$8.90M$9.24M$7.79M
Stock-based compensation$106.11M$103.10M$95.11M$92.58M$90.64M$93.36M$77.83M$71.93M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.